Overview

Evaluation of Antiplatelet Effects and Safety of Intraoperative Administration of Ticagrelor Versus Clopidogrel

Status:
Unknown status
Trial end date:
2017-04-01
Target enrollment:
Participant gender:
Summary
This study is designed to test the hypothesis that the onset of the antiplatelet effect 90mg-first-dose of ticagrelor will be more rapid and greater than 300mg-loading-dose of clopidogrel evaluated by P2Y12 reaction units measured by Verify NowTM P2Y12 assay at 1 hour in patients undergoing one-stop Hybrid coronary revascularization(HCR).
Phase:
Phase 4
Details
Lead Sponsor:
Yongjian Wu
Treatments:
Clopidogrel
Ticagrelor
Ticlopidine